Transphorm’s Gen III JEDEC-Qualified GaN to Power Wentai’s New 1.6 kW Titanium ATX PC Gaming Power Supply
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability, first JEDEC- and AEC-Q101 qualified high-voltage (HV) Gallium Nitride (GaN) semiconductors—today confirmed that Taiwanese Original Equipment Manufacturer Wentai Technology Corporation has developed a Titanium ATX gaming power supply series called Aidan. The flagship product, the Aidan-T1616, uses Transphorm’s TP65H050WS Gen III 50 milliohm GaN FET in an interleaved CCM boost PFC. The result is a fully-modular, low-noise 1616 W 80 PLUS® Titanium power supply unit (PSU) with close to 95 percent efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190528005323/en/
Wentai's new 1.6 kW ATX PC Gaming PSU uses Transphorm's Gen III GaN FETs to achieve an 80 PLUS® Titanium power rating with approx. 95% efficiency. (Photo: Business Wire)
The Aidan ATX PSU series targets consumer computing markets requiring ultra-high power such as PC gaming, Esports, artificial intelligence (AI), and cryptocurrency mining. When compared to Wentai’s Silicon-based 1.28 kW PSU, the Aidan-T1616 offers 328 W more power and approximately one percent higher efficiency at 50 percent full load—all within the same form factor. This equates to a 20 percent increase in power density.
The high-performant PC market uniquely serves use cases such as immersive gaming, artificial intelligence (AI) and virtual currency mining that requires a large amount of reliable power in comparison to everyday PC use,” said Aidan Liao, Senior RD Director, Wentai. “GaN provided the right technological advantage for us to conceive the Aidan PSU’s design to answer that need. Transphorm’s GaN provided the right quality, reliability and performance advantage for us to ultimately deliver on our vision with a top-quality, fairly priced power supply.”
Wentai’s power system development project occurred over the course of 18 months. Throughout that time, the company worked with Transphorm’s regional application support team whose positive reputation, according to Liao, was another influencing factor behind Wentai choosing Transphorm’s GaN devices.
Scheduled for formal release in early 2020, the Aidan-1616 will be demonstrated in Wentai’s Computex exhibit in Hall 1-1F, Booth Number I1307. The Aidan product line will expand to include PSUs offering various wattages, including 777 W, 888 W, 1111 W, 1288 W, and 1388 W.
About Wentai Technology Corporation
Wentai Technology is an LED lighting and power supply manufacturer. The company’s R&D team has continuously improved its technical and innovative capabilities, enabling Wentai to obtain several patents year over year that meet market demand and customer needs. Headquartered in Taipei, Wentai increases its production capabilities and reduces related costs through the use of its two production facilities located in Shenzhen, China and Suzhou, China.
Welcome to the GaN Revolution!
Transphorm designs and manufactures the highest performance, highest reliability 650 V and 900 V GaN semiconductors for high-voltage power conversion applications. Holding one of the largest IP portfolios (600+ patents), Transphorm produces the industry’s only JEDEC and AEC-Q101 qualified GaN FETs. This is due to a vertically-integrated business approach, which allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm: moving power electronics beyond Silicon limits. Website: transphormusa.com Twitter: @transphormusa
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Velodyne Files Patent Infringement Complaint with ITC Against Hesai and RoboSense16.8.2019 12:00:00 CEST | Press release
Velodyne Lidar, Inc. filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hesai Photonics Technology Co., Ltd. and Suteng Innovation Technology Co., Ltd. (a.k.a. RoboSense) for violations of section 337 of the Tariff Act of 1930 which makes unfair methods of competition and importation of certain products into the United States unlawful. Earlier this week, Velodyne also filed patent infringement complaints against Hesai and RoboSense in the U.S. District Court for the Northern District of California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005041/en/ Velodyne Lidar’s Alpha Puck™, Ultra Puck™ and Puck™ surround view sensors (left to right). (Photo: Business Wire) Velodyne is asking the ITC to investigate these lidar manufacturers for unlawfully importing and selling lidar sensors that infringe Velodyne’s patented lidar technology (U.S. Patent 7,969,558). Velodyne reques
Merz Announces Key Governance Changes16.8.2019 09:26:00 CEST | Press release
Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/ Philip Burchard, CEO of Merz (Photo: Business Wire) Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on ae
FINEOS lists on the Australian Securities Exchange16.8.2019 07:22:00 CEST | Press release
FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005058/en/ FINEOS lists on the Australian Securities Exchange (Photo: Business Wire) FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down. Key areas of growth strategy for FINEOS include: • Inc
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis15.8.2019 20:01:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/ “We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievem
Celsius Network Partners With Bitcoin.com15.8.2019 14:55:00 CEST | Press release
Celsius Network, the industry-leading cryptocurrency platform, has announced a new partnership with Bitcoin.com, the leading resource for Bitcoin trading, news, and updates. Users of Celsius services are now able to purchase BCH, BTC, ETH, and other mutually supported cryptocurrencies through the Celsius app using Bitcoin.com’s advanced crypto trading platform providing low fees, enhanced accessibility to cryptocurrency, and valuable crypto services. With the shared mission of making financial services fair, rewarding, and transparent, Celsius and Bitcoin.com are well-known in the space for offering inclusive services designed to support the needs and interests of their robust communities. Celsius members can earn interest income of up to 10.53% APR on crypto assets and use their coins as collateral to get dollar loans at rates as low as 4.95% without fees or penalties, no minimums or caps, and no lockups. Bitcoin.com makes it easy to buy dozens of crypto assets instantly and without f
Anesthesia Patient Safety Foundation and Patient Safety Movement Foundation Offer $100,000 Patient Safety Curriculum Award15.8.2019 12:58:00 CEST | Press release
The Anesthesia Patient Safety Foundation (APSF), in partnership with the Patient Safety Movement Foundation (PSMF), is now accepting proposals for the Patient Safety Curriculum Award. The $100,000 award will go to an anesthesia education investigator with the intent to modify the PSMF Patient Safety Curriculum to address perioperative patient safety. The awardee will also test the educational efficiency and effectiveness of implementing the curriculum in anesthesia training programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005377/en/ Anesthesia Patient Safety Foundation and Patient Safety Movement Foundation Offer $100,000 Patient Safety Curriculum Award (Graphic: Business Wire) “This important work will add to the considerable value provided by PSMF’s Patient Safety Curriculum,” said Mark Warner, APSF President. “To ensure the safety of patients and achieve our collective goal of zero preventable deaths in hosp